Imperial College London
Portrait Picture

ProfessorJenniferQuint

Faculty of Medicine, School of Public Health

Professor of Respiratory Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 8821j.quint

 
 
//

Location

 

.922Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Roche:2019:10.1186/s13601-019-0255-x,
author = {Roche, N and Campbell, J and Krishnan, J and Brusselle, G and Chisholm, A and Bjermer, L and Thomas, M and van, Ganse E and van, den Berge M and Christoff, G and Quint, J and papadopoulos, N and Price, D},
doi = {10.1186/s13601-019-0255-x},
journal = {Clinical and Translational Allergy},
title = {Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force},
url = {http://dx.doi.org/10.1186/s13601-019-0255-x},
volume = {9},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development. The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness. Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers. Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice.
AU  - Roche,N
AU  - Campbell,J
AU  - Krishnan,J
AU  - Brusselle,G
AU  - Chisholm,A
AU  - Bjermer,L
AU  - Thomas,M
AU  - van,Ganse E
AU  - van,den Berge M
AU  - Christoff,G
AU  - Quint,J
AU  - papadopoulos,N
AU  - Price,D
DO  - 10.1186/s13601-019-0255-x
PY  - 2019///
SN  - 2045-7022
TI  - Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
T2  - Clinical and Translational Allergy
UR  - http://dx.doi.org/10.1186/s13601-019-0255-x
UR  - http://hdl.handle.net/10044/1/67305
VL  - 9
ER  -
Download